GSK’s Q3 results buoyed by long-acting HIV jab
Strong performance in its long-acting HIV preventable has helped GlaxoSmithKline to raise its profit forecasts, with five new long-acting product launches now expected by 2030….
HIV
South Africa to make Gilead’s lenacapavir a ‘public good’
South Africa’s Minister of Health said the country plans to make Gilead’s twice-yearly HIV preventative lenacapavir into a “public good”, adding it would be “affordable…
Patients prefer ViiV’s PrEP jab over Gilead’s – study
The long-acting HIV prevention jab cabotegravir has a higher acceptability rating among patients than lenacapavir, according to a study. ViiV Healthcare, a global specialist HIV…